Subsequently, it has been a controversial issue whether rhEpo and its analog erythropoietin stimulating agents are detrimental for the treatment of anemia in cancer patients by promoting cancer cell survival and angiogenesis [10]–[11], [27]–[29]. This evidence concerns the gene EPO and anemia (phenotype).